Stephen X Skapek

List of Publications by Year
in descending order

Version: 2024-02-01

39 papers	2,514 citations	394421 19 h-index	345221 36 g-index
40 all docs	40 docs citations	40 times ranked	3906 citing authors

#	Article	IF	Citations
1	Rhabdomyosarcoma. Nature Reviews Disease Primers, 2019, 5, 1.	30.5	619
2	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. Cancer Discovery, 2014, 4, 216-231.	9.4	596
3	Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nature Communications, 2015, 6, 8891.	12.8	126
4	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2018, 36, 2770-2777.	1.6	124
5	Safety and efficacy of highâ€dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study. Pediatric Blood and Cancer, 2013, 60, 1108-1112.	1.5	106
6	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	1.6	101
7	Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Cancer Medicine, 2019, 8, 6437-6448.	2.8	90
8	A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncology, The, 2020, 21, 145-161.	10.7	89
9	Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26645.	1.5	82
10	Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma. American Journal of Clinical Pathology, 2013, 140, 82-90.	0.7	74
11	Sarcomas. Pediatric Clinics of North America, 2015, 62, 179-200.	1.8	65
12	Clonality and Evolutionary History of Rhabdomyosarcoma. PLoS Genetics, 2015, 11, e1005075.	3.5	58
13	Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Lowâ€Risk Clinical Features: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 634-639.	1.5	53
14	PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. ELife, 2018, 7, .	6.0	39
15	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics, 2016, 209, 182-194.	0.4	38
16	Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Childrenâ€™s Oncology Group. Scientific Reports, 2020, 10, 12318.	3.3	28
17	Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. Genes and Development, 2019, 33, 626-640.	5.9	27
18	Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes. Cell Reports, 2018, 24, 238-251.	6.4	25

#	Article	IF	Citations
19	Clinical Application of Prognostic Gene Expression Signature in Fusion Geneâ€“Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 4733-4739.	7.0	21
20	HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma. Oncogene, 2021, 40, 578-591.	5.9	20
21	miR-34a is essential for p19Arf-driven cell cycle arrest. Cell Cycle, 2014, 13, 792-800.	2.6	17
22	Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusionâ€“negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2018, 124, 1973-1981.	4.1	14
23	Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Journal of Physical Education and Sports Management, 2019, 5, a004440.	1.2	12
24	Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. British Journal of Cancer, 2021, 124, 1637-1646.	6.4	12
25	Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clinical Cancer Research, 2018, 24, 3888-3897.	7.0	11
26	Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Childrenâ€™s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Journal of Clinical Medicine, 2021, 10, 1416.	2.4	11
27	Odontogenic Myxoma of the Face: Mimicry of Cherubism. Journal of Oral and Maxillofacial Surgery, 2014, 72, 2186-2191.	1.2	10
28	Bayesian Modeling Identifies PLAG1 as a Key Regulator of Proliferation and Survival in Rhabdomyosarcoma Cells. Molecular Cancer Research, 2020, 18, 364-374.	3.4	9
29	The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1557-1562.	1.5	7
30	Identification of De Novo Enhancers Activated by TGFÎ² to Drive Expression of CDKN2A and B in HeLa Cells. Molecular Cancer Research, 2019, 17, 1854-1866.	3.4	6
31	Development of a Data Model and Data Commons for Germ Cell Tumors. JCO Clinical Cancer Informatics, 2020, 4, 555-566.	2.1	6
32	Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases. Scientific Reports, 2016, 6, 20376.	3.3	5
33	Isolation and characterization of mammalian cells expressing theArfpromoter during eye development. BioTechniques, 2014, 56, 239-49.	1.8	3
34	Relationship of fusion protein status and outcome for children with intermediate-risk rhabdomyosarcoma: A Children's Oncology Group report.. Journal of Clinical Oncology, 2012, 30, 9535-9535.	1.6	3
35	Varied manifestations of persistent hyperplastic primary vitreous with graded somatic mosaic deletion of a single gene. Molecular Vision, 2014, 20, 215-30.	1.1	3
36	Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts. Pediatric Blood and Cancer, 2020, 67, e28639.	1.5	2

#	Article	IF	Citations
37	Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Childrenâ€™s Oncology Group. Scientific Reports, 2016, 6, 33429.	3.3	1
38	Testis-specific Arf promoter expression in a transposase-aided BAC transgenic mouse model. Molecular Biology Reports, 2019, 46, 6243-6252.	2.3	0
39	Predictors of pediatric and adult fibrosarcoma survival: Analyses of the Surveillance, Epidemiology, and End Results (SEER) program, 1973-2008.. Journal of Clinical Oncology, 2012, 30, 1576-1576.	1.6	0